Clinical trials: insulin glargine
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.
- Trial name
- NCT03332836
- Testing
- HM12460A
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Type 2
Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
Primary Objective: To demonstrate non-inferiority of once daily injection of insulin glargine (Lantus) plus one injection of mealtime insulin glulisine (Apidra) at the main meal versus twice daily premixed insulin (NovoMix 30/70)…
- Trial name
- BASAAL PLUS (NCT01079364)
- Testing
- Insulin glulisine, Insulin glargine, Premixed insulin (Insulin Aspart 30/70 )
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus
Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients
The study is designed to approve non-inferior efficacy and safety of Insulin RinGlar® compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients.
- Trial name
- NCT04022993
- Testing
- Lantus Solostar, 100 Units/mL Subcutaneous Solution, Insulin RinGlar, 100 Units/mL Subcutaneous Solution
- Where
- 14 sites in Russia
- Volunteers
- 180 people
- Sponsor
- Geropharm
Type 2 Diabetes
The Impact of Food on Blood Sugar in People With Type 2 Diabetes
This study will record the impact of food on blood glucose levels using continuous glucose monitoring (CGM). The investigators think the impact will improve as medication doses are adjusted.
- Trial name
- REACT2 (NCT01237314)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- HealthPartners Institute
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been…
- Trial name
- QWINT-4 (NCT05462756)
- Testing
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Where
- 81 sites in United States, Argentina and 6 more
- Volunteers
- 730 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects
Comparison of efficacy and safety of glargine insulin and metformin as first line drug of patients insufficiently treated with lifestyle intervention.
- Trial name
- GLORY (NCT00857870)
- Testing
- Metformin, Insulin glargine
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- GWT-TUD GmbH
Diabetes Mellitus
The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus
This is an open-label randomised multicenter clinical study to investigate efficacy, safety, and immunogenicity of the drug products: Insulin Glargine biosimilar ® Log-G and its reference Lantus® in type 2 diabetes mellitus…
- Trial name
- NCT04591457
- Testing
- Insulin Glargine Sansulin, Insulin Glargine Pen Injector [Lantus]
- Where
- Indonesia
- Volunteers
- 120 people
- Sponsor
- Universitas Indonesia
Type 2 Diabetes Mellitus
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Primary Objective: To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to week 26 in patients with type 2 diabetes mellitus.
- Trial name
- LIXILAN JP-L (NCT02752412)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine U100 (HOE901), Metformin
- Where
- 122 sites in Japan
- Volunteers
- 513 people
- Sponsor
- Sanofi
Diabetes Mellitus
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast…
- Trial name
- NCT00046501
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus
A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin.
- Trial name
- NCT01476345
- Testing
- LY2963016, Lantus
- Where
- South Africa
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)
Aim of the study is to compare two treatment regimens (insulin Lantus as basal insulin vs insulin NPH) plus oral antidiabetics in type 2 diabetic patients and confirm superiority of insulin glargine.
- Trial name
- COBIN 2 (NCT00659477)
- Testing
- insulin glargine
- Where
- Czechia
- Volunteers
- 117 people
- Sponsor
- Sanofi
Diabetes Mellitus
Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.
The purpose of this study is to determine the Anti-Inflammation Effects of Pioglitazone, twice daily (BID), and Pioglitazone/Metformin Combination Therapy BID in Type 2 Diabetes Subjects Treated with Insulin.
- Trial name
- PIOcomb (NCT00770445)
- Testing
- Pioglitazone and insulin, Pioglitazone and metformin and insulin, Metformin and insulin
- Where
- 18 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic…
- Trial name
- NCT00641056
- Testing
- Exenatide Once Weekly, Insulin Glargine
- Where
- 75 sites in United States, Australia and 14 more
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Primary Objective: To demonstrate the superiority of Soliqua 100/33 versus Lantus in the hemoglobin A1c (HbA1c) change within the overall population.
- Trial name
- LixiLan-D (NCT03434119)
- Testing
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Where
- 85 sites in United States
- Volunteers
- 241 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
- Trial name
- NCT00367445
- Testing
- Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood glucose (blood sugar) control on LY2605541 with insulin glargine after 26 weeks of treatment.
- Trial name
- IMAGINE 4 (NCT01468987)
- Testing
- LY2605541, Insulin Glargine, Insulin Lispro
- Where
- 156 sites in United States, Australia and 23 more
- Volunteers
- 1,369 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.
- Trial name
- NCT02152384
- Testing
- Insulin Peglispro, Insulin Lispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Diabetic Ketoacidosis
Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis
To determine if co-administration of subcutaneous (SQ)Insulin glargine in combination with intravenous (IV) insulin decreases the time to resolution of ketoacidosis and requirement for ICU admission compared to IV insulin with…
- Trial name
- GT-COG (NCT02006342)
- Testing
- Insulin Glargine, Regular Insulin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cystic Fibrosis, Glucose Metabolism Disorders
One Year Glargine Treatment in CFRD Children and Adolescents
Glargine treatment can improve the clinical features in Cystic Fibrosis patients affected by glucose derangements
- Trial name
- NCT00483769
- Testing
- Glargine
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Type 1 Diabetes Mellitus
Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes
Rationale. Degludec is a longer-acting insulin analog compared to glargine and detemir. In a fraction of type 1 diabetic patients, insulin glargine and insulin detemir may not achieve 24h coverage, reflected by raising pre-dinner…
- Trial name
- Basal21 (NCT02360254)
- Testing
- Insulin degludec
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- University of Padova